M.I.T. Consulting Ltd.

Strategic analysis of the pharma business

08.10.2008

In volatile markets pharma landscape is changing with an increasing speed and strategies become also unexpectedly out of date or eviscerated. Population chenges, disease and economic epidemiology seem currently rather foreseeable and the need for effective and safe drugs is bigger than ever. Still cost containment prevails as well as unwillingness to support incremental innovation may be fading in the world where the lead and development times are typically very long. Furthermore, the number of drugs in phase I & II development is all time high but still drugs in late phase development as well as  the introduction of new drugs into the market is plateau. Here the pharma terrain is becoming foggy.

Become familiar with the landscape and main change drivers with our complimentary report “Strategic analysis of the pharma business“,which will be periodically updated.

Please visit our site and download at M.I.T. Reports.

New consultant joins M.I.T. Consulting Ltd.

08.10.2008

Marjut Ranki-Pesonen, MD, PhD. has joined our team. Her background is in pharma industry, ie. Orion Pharma. She has a long history of successfully leading projects from innovative findings to new products and processes including implementation of genomics to drug research. Recently, under her guidance the pharmacogenetic study process was mapped and implemented including a biobank for the management of biological samples and data. Her expertise was utilized by the Ministry of Social Affairs in the evaluation of the needs of a biobank law in Finland. She is well informed of the trends and regulations in pharma industry of biobanks and of biomarker research. Biomarkers are increasingly used to improve success and to manage risks of the research projects in pharma industry. Biomarkers will be the key issues to guide the development towards individualized therapies. Functioning networks with big pharma pharmacogenomic leaders is essential to keeping up with trends in this fast evolving field.

Marjut Ranki-Pesonen's expertise in combining knowledge of basic research and clinical development will be useful in evaluating the potential of early research projects and development candidates. Based on her long experience in R&D and project management Marjut Ranki-Pesonen can add value in mapping and managing R&D related processes and ensuring project implementation. She can also offer valuable guidance in building biobanks both for academic institutions and industry.

M.I.T. Short Report on Finnish pharma market 2007 published

08.10.2008

The Finnish pharma market in 2007 was about 1.85 B€ representing some 0,31 % of the global pharma market. The value of sales to pharmacies was 1.374 B€, up 4.9 % of previous year and the medicine sales to hospitals was 453 M€, up 8.4 %.

In the three years time the top 10 list of best selling products will continue to change radically in Finland, since generic and price pressure is potentially eroding their position.

Changes have been quite big in the past and more, radical changes are forecasted in the future.

Pharma- Building competitive edge programme

08.10.2008

M.I.T. Consulting Ltd. is actively participating in Pharma- Building competitive edge programme established by The Finnish Funding Agency for Technology and Innovation, Tekes. Tekes has engaged M.I.T Consulting to provide special assignment concerning China as a part of the Pharma Programme. Earlier this spring M.I.T. Consulting also submitted an offer to coordinate the whole Pharma Programme covering the years 2008-2011. In the evaluation process of the offers Tekes regarded the coordination proposal of M.I.T. Consulting as the best of all submitted proposals. Proposal downloadable from M.I.T. Reports now.

Strategic Centre for Health and Well-being moves forward

27.04.2009

The SHOK board of Ministry of Employment and the Economy has approved the application for Strategic Centre for Health and Well-being. M.I.T. Consulting has actively contributed this achievement by building the Strategic Research Agenda for Strategic Centre for Health and Well-being

M.I.T. Short Report on Finnish pharma market 2008 published

08.07.2009

M.I.T. Short Report: The Finnish Pharma Market 2008

The Finnish pharma market in 2008 was about 1.97 B€ representing some 0,3 % of the global pharma market. The value of sales to pharmacies was 1.374 B€, up 6.8 % of previous year and the medicine sales to hospitals was 477 M€, up 5.3 %.

Downloadable at M.I.T. Reports

01.09.2009

Lisbeth Forss (M. Sc. (Pharm.)) has joined our team. Her background is in pharma industry i.e Orion Pharma, Finnish Red Cross Blood Service and local marketing companies. She has a history of regulatory affairs and quality management. As project manager of international registration projects she has experience of compilation dossiers for marketing authorisation applications, variation and renewal applications as well as of co-ordination of several registration procedures in the EU (centralised procedure and mutual recognition procedure). She also has experience of developing an administrative and quality assurance system and a good knowledge of Good Distribution Practices (GDP) of medicinal products.

14.03.2010

DNA samples can reveal essential information about hereditary factors related to efficacy and safety of a new pharmaceutical, paving the way for individualized therapy. DNA samples are nowadays regularly collected in connection with clinical trials. They are becoming an important link in ensuring a safe and efficacious dosage of the new pharmaceutical and in improving its risk benefit ratio in correctly identified groups of patients. Information gained from studying the genetic samples is reliable only if samples are available from a large and representative group of study subjects.

Similarly, crucial information collected during large clinical trial programmes and summarized in registries and databases can reveal important knowledge for the benefit of physicians and patients.

Since utilization of DNA samples, registries and databases as a part of clinical trials is a relatively new phenomenon a pharmaceutical company may phase unforeseen challenges regarding submission of protocols, pharmacogenetic substudy protocols, and their amendments as well as patient information and informed consent and when dealing with ethical committees and regulatory bodies.

M.I.T. Consulting can help you in reaching your goal and limit the time wasted.

Our experts at your service

Marjut Ranki-Pesonen, MD, PhD                    

Senior consultant with expertise in pharmacogenetics                                       

Veijo Ikonen, MSc

Senior consultant with expertise in risk analysis and management

18.12.2010

M.I.T. Consulting lahjoitti Joulutervehdyksiin varatun summan Mannerheimin lastensuojeluliitolle Hyvä Joulumieli-keräykseen. M.I.T. Consulting toivottaa Hyvää Joulua ja menestyksekästä Uutta Vuotta kaikille yhteistyökumppaneilleen.

18.12.2011

M.I.T. Consulting lahjoitti Joulutervehdyksiin varatun summan Kirkon ulkomaanavun kautta käytettäväksi inhimillisen hädän helpotamiseen. M.I.T. Consulting toivottaa Hyvää Joulua ja menestyksekästä Uutta Vuotta kaikille yhteistyökumppaneilleen.

M.I.T. Consulting Oy on kustantanut kirjan "Kilpirauhanen ja kilpirauhassairaudet - kirja potilaalle"

29.05.2013

M.I.T. Consulting Oy on kustantanut kirjan "Kilpirauhanen ja kilpirauhassairaudet - kirja potilaalle" kirjoittajana LKT, sisätautiopin dosentti Esa Soppi. Kirjan esite ja tilauslomake on ladattavissa Publications & News osion alta.

Kirjaa myös saatavissa ainakin kirjakaupoista Akateeminen ja Gaudeamus.